Mitotane
| Clinical data | |
|---|---|
| Trade names | Lysodren |
| Other names | 1,1-(Dichlorodiphenyl)-2,2-dichloroethane; o,p'-DDD |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608050 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 40% |
| Protein binding | 6% |
| Elimination half-life | 18–159 days |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.152 |
| Chemical and physical data | |
| Formula | C14H10Cl4 |
| Molar mass | 320.03 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| Melting point | 76 to 78 °C (169 to 172 °F) |
| |
| |
| (verify) | |
Mitotane, sold under the brand name Lysodren, is a steroidogenesis inhibitor and cytostatic antineoplastic medication which is used in the treatment of adrenocortical carcinoma and Cushing's syndrome. It is a derivative of the early insecticide DDT and an isomer of p,p'-DDD (4,4'-dichlorodiphenyldichloroethane) and is also known as 2,4'-(dichlorodiphenyl)-2,2-dichloroethane (o,p'-DDD).